TITLE

Nilotinib, dasatinib or imatinib in CML: no clear winner

AUTHOR(S)
Cooper, Nick
PUB. DATE
June 2012
SOURCE
PharmacoEconomics & Outcomes News;6/23/2012, Issue 656, p7
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
Chronic myeloid leukaemia (CML) is characterised by three distinct phases: chronic phase (CP), accelerated phase (AP) and blast crisis (BC). CML is now largely treated with tyrosine kinase inhibitors (TKIs), such as the first- generation imatinib [Glivec] and the newer second-generation dasatinib [Sprycel] and nilotinib [Tasigna], which have led to dramatically improved survival rates since their introduction in the last decade. However, costs also play a part in treatment decisions. A number of studies presented at the 17th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) [Washington, DC, USA; June 2012] evaluated the costs and outcomes associated with the use of the three drugs across a range of settings.
ACCESSION #
77709294

 

Related Articles

  • In vitro effects of imatinib on CD34+ cells of patients with chronic myeloid leukemia in the megakaryocytic crisis phase. FANKAI MENG; WEN ZENG; LIFANG HUANG; SHUANG QIN; NINGNING MIAO; HANYING SUN; CHUNRUI LI // Oncology Letters;2014, Vol. 7 Issue 3, p791 

    Imatinib is a tailored drug for the treatment of chronic myeloid leukemia (CML), and has substantial activity and a favorable safety profile when used as a single agent in patients with CML in myeloid blast crisis. The megakaryocytic blast crisis in CML occurs rarely and carries a poor...

  • The Accelerated Approval of Oncologic Drugs. Prasad, Vinay; Mailankody, Sham // JAMA: Journal of the American Medical Association;1/22/2014, Vol. 311 Issue 4, p353 

    The authors discuss the lessons learned on the accelerated approval of the BCR-ABL tyrosine kinase inhibitor ponatinib for the treatment of chronic myeloid leukemia (CML). They note that ponatinib illustrates core tension inherent in the Accelerated Approval program. They state that the drug...

  • Second-Generation Tyrosine Kinase Inhibitors (Tki) as Salvage Therapy for Resistant or Intolerant Patients to Prior TKIs. Breccia, Massimo; Alimena, Giuliana // Mediterranean Journal of Hematology & Infectious Diseases;2014, Vol. 6 Issue 1, p1 

    With the advent of target therapies, imatinib became the mainstay for treatment of chronic myeloid leukemia. However, despite the brilliant results obtained with this drug, more than 30% of patients discontinue therapy in long-term due to several reasons, including failure and/or intolerance....

  • A Critical History of Chromic Myeloid Leukemia. Baccarani, Michele; Pane, Fabrizio // Mediterranean Journal of Hematology & Infectious Diseases;2014, Vol. 6 Issue 1, p1 

    The author reflects on various developments in treatment of chronic myeloid leukemia (CML), a cancer of white blood cells (WBCs). Topics discussed include development of targeted treatments for CML such as by targeting the tyrosine kinase inhibitors (TKIs), history of treatment of CML such as by...

  • BCR-ABL mutants spread resistance to non-mutated cells through a paracrine mechanism. Liu, J.; Joha, S.; Idziorek, T.; Corm, S.; Hetuin, D.; Philippe, N.; Preudhomme, C.; Quesnel, B. // Leukemia (08876924);Apr2008, Vol. 22 Issue 4, p791 

    Patients with chronic myeloid leukemia who become resistant to the Abl kinase inhibitor imatinib can be treated with dasatinib. This sequential treatment can lead to BCR-ABL mutations conferring broad resistance to kinase inhibitors. To model the evolution of resistance, we exposed the mouse...

  • Tyrosine Kinase Inhibitors and Interferon. Dimou, Maria; Panayiotidis, Panagiotis // Mediterranean Journal of Hematology & Infectious Diseases;2014, Vol. 6 Issue 1, p1 

    The use of interferon-a (INF) in chronic myeloid leukemia, when it started in the 80s, was considered as a breakthrough in the therapy of this disease; INF administered alone or in combination with aracytin was the standard choice for treatment for Chronic Myeloid Leukemia (CML) patients unfit...

  • Chronic Myelocytic Leukemia -- Part II: Approaches to and Molecular Monitoring of Therapy. Randolph, Tim R. // Clinical Laboratory Science;Winter2005, Vol. 18 Issue 1, p49 

    Focuses on a study which presented the approaches to and molecular monitoring of therapy for chronic myelocytic leukemia (CML). Evolution of the therapeutic approaches for the disease; Effectiveness of the Imatinib therapy as measured by molecular methods; Strategies for the management of CML...

  • FDA actions. Elliott, William T. // Infectious Disease Alert;Dec2012 Pharmacology Watch, p2 

    The article offers information on a drug approved by the U.S. Food and Drug Administratioin (FDA) for treating chronic myelogenous leukemia (CML) with the tyrosine kinase inhibitors (TKIs) therapy such as perampanel for patients with partial onset seizures.

  • Cancer: Next-generation CML therapy. Aranda, Victoria // Nature Medicine;Jan2013, Vol. 19 Issue 1, p28 

    The article focuses on a research which found that a novel BCR-ABL inhibitor can be used for treating patients with chronic myeloid leukemia (CML).

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics